Feeds:
Posts
Comments

Posts Tagged ‘Tang Capital Partners’

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) yesterday announced that the US Food and Drug Administration (FDA) had granted marketing approval following its Phase III clinical study of Fanapt™ (iloperidone). Tang Capital Partners has ended its proxy contest by withdrawing its nominations of director candidates for election to VNDA’s Board of Directors and its stockholder proposal to liquidate [...]

Read Full Post »

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has reported its results for the first quarter ended March 31, 2009. We’ve been following VNDA (see our post archive here) because it’s trading below its net cash value and Tang Capital Partners (TCP) has called for the company to “cease operations immediately, liquidate [VNDA]’s assets and distribute all remaining capital [...]

Read Full Post »

Tang Capital Partners has filed a preliminary proxy statement for the Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) 2009 Annual Meeting of Stockholders urging stockholders to support Tang Capital Partners’ slate of two director nominees, Kevin C. Tang and Andrew D. Levin, M.D., Ph.D. We’ve been following VNDA (see our post archive here) because it’s trading below its [...]

Read Full Post »

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is trading below its net cash value and an investor, Tang Capital Partners (TCP), has called for the company to “cease operations immediately, liquidate [VNDA]‘s assets and distribute all remaining capital to the Stockholders.” At the company’s $0.78 closing price yesterday, VNDA has a market capitalization of $20.8M. We estimate the [...]

Read Full Post »

Follow

Get every new post delivered to your Inbox.

Join 812 other followers